뱀 항독소 시장 - 점유율, 규모, 동향, 산업 분석 보고서 : 유형별, 작용기전별, 최종 사용자별, 지역별, 부문별 예측(2024-2032년)

The global snake antivenom market size is expected to reach USD 636.85 Million by 2032, according to a new study by Polaris Market Research. The report "Snake Antivenom Market Share, Size, Trends, Industry Analysis Report, By Type (Polyvalent Heterologous, Monovalent Heterologous, Homologous, and Small Molecule Anti-Toxins); By Mode of Action; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of snakebites as a common public health issue across various regions and increased demand for effective venom neutralizing solutions or treatments, driving the market's growth. Awareness among healthcare professionals about the identification, management, and treatment of snakebites, fostering the demand for antivenoms. Additionally, growing advances in R&D that results in the creation of more effective antivenom formulations and advancements in diagnostics and treatment methods, are further anticipated to boost market's growth.

For instance, in January 2023, Ophirex Inc., announced that they completed a USD 37 million Series B financing. The funds will be used to continue clinical development and regulatory submission in order to advance broad-spectrum snakebite treatment.

The access to effective, safe, and quality products that are specially tailored to the endemic species has been becoming an important component to reduce the burden of snake bites. At the national level, there is insufficient manufacturing output of antivenoms to meet the clinical needs especially for antivenoms intended for use in region with scarcity of producers. Thus, there is an emerging opportunity for manufacturing or developing antivenoms with enhanced capabilities, which will also bode well for market's growth.

For instance, according to a report published by the Indian Journal of Medical Research in April 2023, India is focusing on a national programme for prevention & control of snakebite in India that encourages the development new and effective antivenoms.

Furthermore, there is a growing emphasis on research & development activities in the field of snake antivenom which mainly includes activities like creation of new improved treatment formulations and improving the overall treatment outcomes. It helps patients quickly recover from the pain and reduces the number of constantly rising deaths due to snakebites across the globe.

Snake Antivenom Market Report Highlights

Polyvalent heterologous segment accounted for the largest share, due to its higher effectiveness and preference over alternative options

Neurotoxic segment held the maximum share, on account of rising prevalence of neurotoxic snakebites and its adoption among healthcare professionals

Hospitals & clinics segment will grow at fastest pace, owing to significant increase in patient population and improvements in hospitals infrastructure

Asia Pacific is expected to dominated the global market, due to rising incidences of snakebites and number of deaths occurs due to thus in the region

The key market players include Boehringer-Ingelheim Thermo Fisher, Hamilton Company, Incepta Vaccine, Novo Nordisk, Rare Disease Therapeutics, and Bioclon

Polaris Market Research has segmented the snake antivenom market report based on type, mode of action, end user, and region:

Snake Antivenom, Type Outlook (Revenue - USD Million, 2019 - 2032)

• Polyvalent Heterologous
• Monovalent Heterologous
• Homologous
• Small Molecule Anti-Toxins

Snake Antivenom, Mode of Action Outlook (Revenue - USD Million, 2019 - 2032)

• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

Snake Antivenom, End User Outlook (Revenue - USD Million, 2019 - 2032)

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

Snake Antivenom, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Snake Antivenom Market Insights

• 4.1. Snake Antivenom Market - End User Snapshot
• 4.2. Snake Antivenom Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Growing incidences of snakebites and rising investments on R&D activities spurring the global market growth.
    • 4.2.1.2. Government Initiatives and Funding.
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Costs of Antivenom Production.
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Snake Antivenom Market End User Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Snake Antivenom Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Snake Antivenom Market, by Type, 2019-2032 (USD Million)
• 5.3. Polyvalent Heterologous
  • 5.3.1. Global Snake Antivenom Market, by Polyvalent Heterologous, by Region, 2019-2032 (USD Million)
• 5.4. Monovalent Heterologous
  • 5.4.1. Global Snake Antivenom Market, by Monovalent Heterologous, by Region, 2019-2032 (USD Million)
• 5.5. Homologous
  • 5.5.1. Global Snake Antivenom Market, by Homologous, by Region, 2019-2032 (USD Million)
• 5.6. Small Molecule
  • 5.6.1. Global Snake Antivenom Market, by Small Molecule, by Region, 2019-2032 (USD Million)

6. Global Snake Antivenom Market, by Mode of Action

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
• 6.3. Cytotoxic
  • 6.3.1. Global Snake Antivenom Market, by Cytotoxic, by Region, 2019-2032 (USD Million)
• 6.4. Neurotoxic
  • 6.4.1. Global Snake Antivenom Market, by Neurotoxic, by Region, 2019-2032 (USD Million)
• 6.5. Haemotoxic
  • 6.5.1. Global Snake Antivenom Market, by Haemotoxic, by Region, 2019-2032 (USD Million)
• 6.6. Cardiotoxic
  • 6.6.1. Global Snake Antivenom Market, by Cardiotoxic, by Region, 2019-2032 (USD Million)
• 6.7. Myotoxic
  • 6.7.1. Global Snake Antivenom Market, by Myotoxic, by Region, 2019-2032 (USD Million)
• 6.8. Others
  • 6.8.1. Global Snake Antivenom Market, by Others, by Region, 2019-2032 (USD Million)

7. Global Snake Antivenom Market, by End User

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Snake Antivenom Market, by End User, 2019-2032 (USD Million)
• 7.3. Hospitals & Clinics
  • 7.3.1. Global Snake Antivenom Market, by Hospitals & Clinics, By Region, 2019-2032 (USD Million)
• 7.4. Ambulatory Surgical Centers
  • 7.4.1. Global Snake Antivenom Market, by Ambulatory Surgical Centers, By Region, 2019-2032 (USD Million)
• 7.5. Research Institutes
  • 7.5.1. Global Snake Antivenom Market, by Research Institutes, By Region, 2019-2032 (USD Million)
• 7.6. Others
  • 7.6.1. Global Snake Antivenom Market, by Others, By Region, 2019-2032 (USD Million)

8. Global Snake Antivenom Market, by Geography

• 8.1. Key findings
• 8.2. Introduction
  • 8.2.1. Snake Antivenom Market Assessment, By Geography, 2019-2032 (USD Million)
• 8.3. Snake Antivenom Market - North America
  • 8.3.1. North America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 8.3.2. North America: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 8.3.3. North America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.3.4. Snake Antivenom Market - U.S.
    • 8.3.4.1. U.S.: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.3.4.2. U.S.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.3.4.3. U.S.: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.3.5. Snake Antivenom Market - Canada
    • 8.3.5.1. Canada: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.3.5.2. Canada.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.3.5.3. Canada: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
• 8.4. Snake Antivenom Market - Europe
  • 8.4.1. Europe: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 8.4.2. Europe.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 8.4.3. Europe: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.4. Snake Antivenom Market - UK
    • 8.4.4.1. UK: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.4.2. UK.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.4.3. UK: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.5. Snake Antivenom Market - France
    • 8.4.5.1. France: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.5.2. France.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.5.3. France: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.6. Snake Antivenom Market - Germany
    • 8.4.6.1. Germany: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.6.2. Germany.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.6.3. Germany: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.7. Snake Antivenom Market - Italy
    • 8.4.7.1. Italy: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.7.2. Italy.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.7.3. Italy: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.8. Snake Antivenom Market - Spain
    • 8.4.8.1. Spain: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.8.2. Spain.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.8.3. Spain: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.9. Snake Antivenom Market - Netherlands
    • 8.4.9.1. Netherlands: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.9.2. Netherlands.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.9.3. Netherlands: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.4.10. Snake Antivenom Market - Russia
    • 8.4.10.1. Russia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.4.10.2. Russia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.4.10.3. Russia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
• 8.5. Snake Antivenom Market - Asia Pacific
  • 8.5.1. Asia Pacific: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 8.5.2. Asia Pacific.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 8.5.3. Asia Pacific: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.4. Snake Antivenom Market - China
    • 8.5.4.1. China: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.4.2. China.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.4.3. China: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.5. Snake Antivenom Market - India
    • 8.5.5.1. India: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.5.2. India.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.5.3. India: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.6. Snake Antivenom Market - Malaysia
    • 8.5.6.1. Malaysia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.6.2. Malaysia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.6.3. Malaysia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.7. Snake Antivenom Market - Japan
    • 8.5.7.1. Japan: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.7.2. Japan.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.7.3. Japan: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.8. Snake Antivenom Market - Indonesia
    • 8.5.8.1. Indonesia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.8.2. Indonesia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.8.3. Indonesia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.5.9. Snake Antivenom Market - South Korea
    • 8.5.9.1. South Korea: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.5.9.2. South Korea.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.5.9.3. South Korea: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
• 8.6. Snake Antivenom Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 8.6.2. Middle East & Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 8.6.3. Middle East & Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.6.4. Snake Antivenom Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.6.4.2. Saudi Arabia.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.6.4.3. Saudi Arabia: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.6.5. Snake Antivenom Market - UAE
    • 8.6.5.1. UAE: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.6.5.2. UAE.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.6.5.3. UAE: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.6.6. Snake Antivenom Market - Israel
    • 8.6.6.1. Israel: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.6.6.2. Israel.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.6.6.3. Israel: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.6.7. Snake Antivenom Market - South Africa
    • 8.6.7.1. South Africa: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.6.7.2. South Africa.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.6.7.3. South Africa: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
• 8.7. Snake Antivenom Market - Latin America
  • 8.7.1. Latin America: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
  • 8.7.2. Latin America.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
  • 8.7.3. Latin America: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.7.4. Snake Antivenom Market - Mexico
    • 8.7.4.1. Mexico: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.7.4.2. Mexico.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.7.4.3. Mexico: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.7.5. Snake Antivenom Market - Brazil
    • 8.7.5.1. Brazil: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.7.5.2. Brazil.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.7.5.3. Brazil: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)
  • 8.7.6. Snake Antivenom Market - Argentina
    • 8.7.6.1. Argentina: Snake Antivenom Market, by Type, 2019-2032 (USD Million)
    • 8.7.6.2. Argentina.: Snake Antivenom Market, by End User, 2019-2032 (USD Million)
    • 8.7.6.3. Argentina: Snake Antivenom Market, by Mode of Action, 2019-2032 (USD Million)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Bharat Serums and Vaccine Limited
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Bioclon Institute
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. Boehringer-Ingelheim Thermo Fisher
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Boston Scientific Corporation
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. BTG International Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. CSL Limited
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Hamilton Company
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Incepta Vaccine Ltd.
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Inosan Biopharma
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Merck & Co. Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. MicroPharm
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. Novo Nordisk A/S
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development
• 10.13. Owen Mumford Ltd.
  • 10.13.1. Company Overview
  • 10.13.2. Financial Performance
  • 10.13.3. Product Benchmarking
  • 10.13.4. Recent Development
• 10.14. Pfizer Inc.
  • 10.14.1. Company Overview
  • 10.14.2. Financial Performance
  • 10.14.3. Product Benchmarking
  • 10.14.4. Recent Development
• 10.15. Rare Disease Therapeutics Inc.
  • 10.15.1. Company Overview
  • 10.15.2. Financial Performance
  • 10.15.3. Product Benchmarking
  • 10.15.4. Recent Development
• 10.16. VINS Bioproducts Limited
  • 10.16.1. Company Overview
  • 10.16.2. Financial Performance
  • 10.16.3. Product Benchmarking
  • 10.16.4. Recent Development